Last reviewed · How we verify
Symbicort pMDI + budesonide HFA pMDI
Symbicort pMDI + budesonide HFA pMDI is a Inhaled corticosteroid Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
Budesonide is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.
Budesonide is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Symbicort pMDI + budesonide HFA pMDI |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Budesonide suppresses inflammatory cytokine production and immune cell recruitment in the airways, reducing mucus production, airway edema, and bronchial hyperresponsiveness. The pMDI (pressurized metered-dose inhaler) and HFA (hydrofluoroalkane) formulations deliver the drug directly to the lungs for local anti-inflammatory effects with minimal systemic absorption.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Oral candidiasis
- Hoarseness
Key clinical trials
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy (PHASE2)
- A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma. (PHASE3)
- An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma (PHASE3)
- Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma (PHASE3)
- Titratable Dosing in Moderate to Severe Asthmatics (PHASE3)
- Symbicort Onset of Action 2 (PHASE3)
- A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symbicort pMDI + budesonide HFA pMDI CI brief — competitive landscape report
- Symbicort pMDI + budesonide HFA pMDI updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Symbicort pMDI + budesonide HFA pMDI
What is Symbicort pMDI + budesonide HFA pMDI?
How does Symbicort pMDI + budesonide HFA pMDI work?
What is Symbicort pMDI + budesonide HFA pMDI used for?
Who makes Symbicort pMDI + budesonide HFA pMDI?
What drug class is Symbicort pMDI + budesonide HFA pMDI in?
What development phase is Symbicort pMDI + budesonide HFA pMDI in?
What are the side effects of Symbicort pMDI + budesonide HFA pMDI?
What does Symbicort pMDI + budesonide HFA pMDI target?
Related
- Drug class: All Inhaled corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Respiratory / Pulmonology
- Indication: Drugs for Asthma maintenance therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD)
- Compare: Symbicort pMDI + budesonide HFA pMDI vs similar drugs
- Pricing: Symbicort pMDI + budesonide HFA pMDI cost, discount & access